Related references
Note: Only part of the references are listed.10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022
DIABETES CARE (2022)
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis
Rajiv Agarwal et al.
EUROPEAN HEART JOURNAL (2022)
Alterations of sodium-hydrogen exchanger 1 function in response to SGLT2 inhibitors: what is the evidence?
Surasak Wichaiyo et al.
HEART FAILURE REVIEWS (2022)
Esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker (MRB) in hypertension and chronic kidney disease
Ningning Wan et al.
JOURNAL OF HUMAN HYPERTENSION (2021)
Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes
Gerasimos Filippatos et al.
CIRCULATION (2021)
Antihypertensive effects and safety of esaxerenone in patients with moderate kidney dysfunction
Sadayoshi Ito et al.
HYPERTENSION RESEARCH (2021)
Crosstalk between Sodium-Glucose Cotransporter Inhibitors and Sodium-Hydrogen Exchanger 1 and 3 in Cardiometabolic Diseases
Al-Anood Al-Shamasi et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage
Peter Kolkhof et al.
AMERICAN JOURNAL OF NEPHROLOGY (2021)
Finerenone: First Approval
James E. Frampton
DRUGS (2021)
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes
Bertram Pitt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
Stefan D. Anker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Exploring the Food and Drug Administration's review and approval of Entresto (sacubitril/valsartan)
Ashley L. Eadie et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2021)
The global epidemiology of hypertension
Katherine T. Mills et al.
NATURE REVIEWS NEPHROLOGY (2020)
Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial
Hiddo J. L. Heerspink et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2020)
Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus A Scientific Statement From the American Heart Association
Suzanne Arnold et al.
CIRCULATION (2020)
2020 International Society of Hypertension Global Hypertension Practice Guidelines
Thomas Unger et al.
HYPERTENSION (2020)
Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease Results of the VERTIS CV Trial
Francesco Cosentino et al.
CIRCULATION (2020)
Blood pressure control in type 2 diabetes mellitus with arterial hypertension. The important ancillary role of SGLT2-inhibitors and GLP1-receptor agonists
C. Berraa et al.
PHARMACOLOGICAL RESEARCH (2020)
Mineralocorticoid Receptor Antagonists: a Comprehensive Review of Finerenone
Juan Simon Rico-Mesa et al.
CURRENT CARDIOLOGY REPORTS (2020)
Sacubitril/Valsartan Neprilysin Inhibition 5 Years After PARADIGM-HF
Kieran F. Docherty et al.
JACC-HEART FAILURE (2020)
Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN) Phase 3 Randomized Controlled Clinical Trial
Sadayoshi Ito et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2020)
Potential mechanisms of beneficial effect of sacubitril/valsartan on glycemic control
Jelena P. Seferovic et al.
THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM (2020)
Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction Subanalysis From the DECLARE-TIMI 58 Trial
Remo H. M. Furtado et al.
CIRCULATION (2019)
B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan The PARADIGM-HF Trial
Peder Langeland Myhre et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
V. Perkovic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Antihypertensive effect of sacubitril/valsartan: a meta-analysis
Renato De Vecchis et al.
MINERVA CARDIOANGIOLOGICA (2019)
Dapagliflozin: A Review in Type 2 Diabetes
Sohita Dhillon
DRUGS (2019)
Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial
Milton Packer et al.
EUROPEAN JOURNAL OF HEART FAILURE (2019)
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Hertzel C. Gerstein et al.
LANCET (2019)
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Mansoor Husain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition
Pouya Saeedi et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2019)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
J. J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Effect of intensive blood pressure control in patients with type 2 diabetes mellitus over 9 years of follow-up: A subgroup analysis of high-risk ACCORDION trial participants
Leo F. Buckley et al.
DIABETES OBESITY & METABOLISM (2018)
Empagliflozin: A Review in Type 2 Diabetes
James E. Frampton
DRUGS (2018)
Hypertension with diabetes mellitus: physiology and pathology
Mitsuru Ohishi
HYPERTENSION RESEARCH (2018)
Glycated hemoglobin correlates with arterial stiffness and endothelial dysfunction in patients with resistant hypertension and uncontrolled diabetes mellitus
Beatriz Moreno et al.
JOURNAL OF CLINICAL HYPERTENSION (2018)
Nebivolol: An Appealing, Awaited and Nitric Oxide Potentiator Drug for the Treatment of Heart Failure
Aryendu Kumar Saini et al.
JOURNAL OF YOUNG PHARMACISTS (2018)
Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015
Mohammad H. Forouzanfar et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial
Jelena P. Seferovic et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes
Shin Kawasoe et al.
BMC PHARMACOLOGY & TOXICOLOGY (2017)
Effect of Intensive Versus Standard Blood Pressure Treatment According to Baseline Prediabetes Status: A Post Hoc Analysis of a Randomized Trial
Adam P. Bress et al.
DIABETES CARE (2017)
Diabetes and Hypertension: A Position Statement by the American Diabetes Association
Ian H. de Boer et al.
DIABETES CARE (2017)
Differential Metabolic Effects of Beta-Blockers: an Updated Systematic Review of Nebivolol
Maria Marketou et al.
CURRENT HYPERTENSION REPORTS (2017)
Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists
Sten Madsbad
DIABETES OBESITY & METABOLISM (2016)
Association of Thiazide-Type Diuretics With Glycemic Changes in Hypertensive Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials
Xiaodan Zhang et al.
JOURNAL OF CLINICAL HYPERTENSION (2016)
Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis
Xinfang Xie et al.
LANCET (2016)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Hypertension treatment in the Asia-Pacific: the role of and treatment strategies with nebivolol
Cheol-Ho Kim et al.
HEART ASIA (2016)
Sympathetic Nervous System, Hypertension, Obesity and Metabolic Syndrome
Gino Seravalle et al.
HIGH BLOOD PRESSURE & CARDIOVASCULAR PREVENTION (2016)
Third-Generation Beta-Adrenoceptor Antagonists in the Treatment of Hypertension and Heart Failure
Filip Y. Fisker et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2015)
A Review of Nebivolol Pharmacology and Clinical Evidence
Justin Fongemie et al.
DRUGS (2015)
Lowering blood pressure in diabetes
Seema Kang
LANCET DIABETES & ENDOCRINOLOGY (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
Jackson T. Wright et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Blood Pressure Lowering in Type 2 Diabetes A Systematic Review and Meta-analysis
Connor A. Emdin et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Functional Role of Glucose Metabolism, Osmotic Stress, and Sodium-Glucose Cotransporter Isoform-Mediated Transport on Na+/H+ Exchanger Isoform 3 Activity in the Renal Proximal Tubule
Thaissa Dantas Pessoa et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2014)
Canagliflozin: First Global Approval
Shelley Elkinson et al.
DRUGS (2013)
Diabetes Mellitus and Vascular Disease
James R. Sowers
HYPERTENSION (2013)
Effect of calcium channel blockers on incidence of diabetes: a meta-analysis
Hiroshi Noto et al.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2013)
Hyperinsulinemia Does Not Change Atherosclerosis Development in Apolipoprotein E Null Mice
Christian Rask-Madsen et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2012)
The Assessment of Endothelial Function From Research Into Clinical Practice
Andreas J. Flammer et al.
CIRCULATION (2012)
Diabetes and Hypertension: Is There a Common Metabolic Pathway?
Bernard M. Y. Cheung et al.
CURRENT ATHEROSCLEROSIS REPORTS (2012)
The Effects of Newer Beta-Adrenoceptor Antagonists on Vascular Function in Cardiovascular Disease
Markus Wehland et al.
CURRENT VASCULAR PHARMACOLOGY (2012)
Preventing β-Cell Loss and Diabetes With Calcium Channel Blockers
Guanlan Xu et al.
DIABETES (2012)
Diverging Association of Reduced Glomerular Filtration Rate and Albuminuria With Coronary and Noncoronary Events in Patients With Type 2 Diabetes The Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study
Anna Solini et al.
DIABETES CARE (2012)
Diabetes and hypertension: the bad companions
Ele Ferrannini et al.
LANCET (2012)
Clinical Importance of Assessment of Type 2 Diabetes Mellitus with Visceral Obesity. A Japanese Perspective
Ken Kishida et al.
CURRENT DIABETES REVIEWS (2012)
Blood Pressure and the Risk of Developing Diabetes in African Americans and Whites ARIC, CARDIA, and the Framingham Heart Study
Gina S. Wei et al.
DIABETES CARE (2011)
Cardiovascular Outcomes in Framingham Participants With Diabetes The Importance of Blood Pressure
Guanmin Chen et al.
HYPERTENSION (2011)
Loss of Insulin Signaling in Vascular Endothelial Cells Accelerates Atherosclerosis in Apolipoprotein E Null Mice
Christian Rask-Madsen et al.
CELL METABOLISM (2010)
Oxidative Stress and Diabetic Complications
Ferdinando Giacco et al.
CIRCULATION RESEARCH (2010)
Small artery structure and function in hypertension
Anthony M. Heagerty et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2010)
Cardiovascular Events During Differing Hypertension Therapies in Patients With Diabetes
Michael A. Weber et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Nebivolol: A Third-Generation beta-Blocker for Hypertension
Judy W. M. Cheng
CLINICAL THERAPEUTICS (2009)
Insufficient Control of Blood Pressure and Incident Diabetes
Raffaele Izzo et al.
DIABETES CARE (2009)
Addition of Angiotensin Receptor Blockade or Mineralocorticoid Antagonism to Maximal Angiotensin-Converting Enzyme Inhibition in Diabetic Nephropathy
Uzma F. Mehdi et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
The role of interleukins in insulin resistance and type 2 diabetes mellitus
Bruno Feve et al.
NATURE REVIEWS ENDOCRINOLOGY (2009)
Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial-blood pressure lowering arm and the relative influence of antihypertensive medication
Ajay K. Gupta et al.
DIABETES CARE (2008)
Aldosterone in salt-sensitive hypertension and metabolic syndrome
Toshiro Fujita
JOURNAL OF MOLECULAR MEDICINE-JMM (2008)
Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial
S. Yusuf et al.
LANCET (2008)
Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients
Kenneth Jamerson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Meta-analysis of 94,492 patients with hypertension treated with beta Blockers to determine the risk of new-onset diabetes Mellitus
Sripal Bangalore et al.
AMERICAN JOURNAL OF CARDIOLOGY (2007)
Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial
A. Patel et al.
LANCET (2007)
Impact of metabolic syndrome on the development of cardiovascular disease in a general Japanese population - The Hisayama study
Toshiharu Ninomiya et al.
STROKE (2007)
Incident diabetes in clinical trials of anti hypertensive drugs: a network meta-analysis
William J. Elliott et al.
LANCET (2007)
Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes - The Framingham Offspring study
JB Meigs et al.
DIABETES (2006)
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA):: a multicentre randomised controlled trial
B Dahlöf et al.
LANCET (2005)
Obesity and hypertension: two epidemics or one?
KP Davy et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2004)
Inflammatory markers and risk of developing type 2 diabetes in women
FB Hu et al.
DIABETES (2004)
Renin-angiotensin system inhibition prevents type 2 diabetes mellitus - Part 2. Overview of physiological and biochemical mechanisms
AJ Scheen
DIABETES & METABOLISM (2004)
Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension - A randomized controlled trial
GL Bakris et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Mechanisms linking angiotensin II and atherogenesis
WB Strawn et al.
CURRENT OPINION IN LIPIDOLOGY (2002)
Vascular function, insulin resistance and fatty acids
HO Steinberg et al.
DIABETOLOGIA (2002)
Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase
H Duplain et al.
CIRCULATION (2001)
Hyperinsulinemia and autonomic nervous system dysfunction in obesity - Effects of weight loss
M Emdin et al.
CIRCULATION (2001)
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
IM Stratton et al.
BMJ-BRITISH MEDICAL JOURNAL (2000)
Share Paper
